An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2019 |
| Start Date: | May 2016 |
| End Date: | March 2020 |
| Contact: | Incyte Corporation Call Center |
| Phone: | 1.855.463.3463 |
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with
advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose
escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on
maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 (dose
expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the
selected monotherapy dose(s) in AML/MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly
differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of
INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in
combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability,
efficacy, PK, and PD of the selected combination dose(s) in Part 3.
advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose
escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on
maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 (dose
expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the
selected monotherapy dose(s) in AML/MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly
differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of
INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in
combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability,
efficacy, PK, and PD of the selected combination dose(s) in Part 3.
Inclusion Criteria:
- Male or female subjects, age 18 years or older.
- Presence of measurable disease that has been confirmed by histology or cytology.
- Must not be a candidate for potentially curative therapy or standard-of-care approved
therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Exclusion Criteria:
- Receipt of anticancer medications, anticancer therapies, or investigational drugs
within the defined interval before the first administration of study drug.
- Any unresolved toxicity ≥ Grade 2 from previous anticancer therapy except for stable
chronic toxicities (≤ Grade 2) not expected to resolve.
- Laboratory and medical history parameters outside Protocol-defined range.
- Known additional malignancy that is progressing or requires active treatment.
We found this trial at
11
sites
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
Click here to add this to my saved trials